Reasons 17-AAG Fees Will Persist Quite High

19, 95% CI 0.77 to 1.83; Z=2.72, p=0.438; figure 5). We also performed subgroup analysis based on the line of treatment and comparators. The aggregated results illustrated that second-line treatment with BE increased the ORR in patients with NSCLC (RR=1.91, HSP inhibitor 95% CI 1.19 to 3.06; p=0.007), but this effect was not observed for first-line treatment with this regimen (RR=0.93, 95% CI 0.59 to 1.46; p=0.747). Patients with NSCLC who were treated with combination therapy had similar ORRs as those treated with either Bev (RR=1.43, 95% CI 0.72 to 2.85; p=0.304) or Erl alone (RR=0.88, 95% CI 0.44 to 1.75; p=0.713). Figure?5 Overall response rate for combination therapy of bevacizumab plus erlotinib with bevacizumab or erlotinib alone. Adverse events All of the included studies reported the data of adverse events.13 14 32�C34 The most common adverse events of grade 3/4 are listed in table 2. The pooled estimates suggested that the combination therapy of Bev and Erl induced a significantly higher rate of rash (RR=2.59, 95% LGK-974 mouse CI 1.40 to 4.79; p=0.002) and diarrhoea (RR=2.73, 95% CI 1.12 to 6.67; p=0.027) as compared with Bev or Erl alone. Table?2 Summary of the RRs of adverse events in patients with non-small-cell lung cancer Discussion The present study was a systematic review and meta-analysis of RCTs with the objective of comparing the combination of Bev and Erl to Bev or Erl alone in the treatment on NSCLC. Our study demonstrated that the combination treatment significantly prolonged PFS and elevated the ORR in the second-line treatment of NSCLC. Bev combined with Erl did not prolong OS in the treatment of NSCLC in either the first or the second line. In Ebastine the subgroup analysis based on comparators, combination therapy significantly improved PFS and ORR, but not OS in the treatment of NSCLC when compared with either Bev or Erl alone. In addition, the addition of Bev to Erl significantly improved PFS in subpopulations of